Mycenax Biotech (4726) — Capital Reinvestment Ratio

Latest as of March 2025: 5.90x

Mycenax Biotech (4726) has a Capital Reinvestment Ratio of 5.90x as of March 2025, meaning it reinvests 6% of its operating cash flow (NT$14.29 Million) in capital expenditures (NT$84.30 Million). Check tangible net worth ratio of Mycenax Biotech to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

5.90x
Capex / Operating Cash Flow

Operating Cash Flow

NT$14.29 Million
TWD

Capital Expenditures

NT$84.30 Million
TWD

Data as of

Mar 2025
Most recent filing

Mycenax Biotech Capital Reinvestment Ratio (2020–2020)

This chart tracks Mycenax Biotech's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see Mycenax Biotech cash conversion from operations.

Annual Capital Reinvestment Ratio for Mycenax Biotech (2020–2020)

Year-by-year Capital Reinvestment Ratio for Mycenax Biotech from 2020 to 2020. See cash generation quality of Mycenax Biotech to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (TWD) Capital Expenditures YoY Change
2020 1.49x NT$174.17 Million NT$260.22 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow